Residency · Residency · Nephrology

Lupus Nephritis

Introduction

Lupus nephritis is one of the most serious manifestations of systemic lupus erythematosus, occurring in approximately 50 to 60 percent of SLE patients, with clinically significant renal disease developing in 25 to 30 percent. It remains a leading cause of morbidity and mortality in SLE, and its impact is disproportionately severe among African Americans, Hispanics, and Asians compared to White populations. The disease demonstrates a striking female predominance with a female-to-male ratio of approximately 9:1 and a peak incidence between 20 and 40 years of age. Despite significant advances in modern immunosuppressive therapies, 10 to 30 percent of patients with lupus nephritis still progress to end-stage renal disease within 15 years of diagnosis.

Pathogenesis

Immune Complex Formation

The pathogenesis of lupus nephritis is driven by a fundamental loss of self-tolerance, resulting in the generation of autoantibodies directed against nuclear antigens including double-stranded DNA, histones, nucleosomes, Smith antigen, and C1q. These autoantibodies form circulating immune complexes that deposit within the glomeruli, or alternatively, antibodies bind to antigens that have been "planted" in the glomerular basement membrane, particularly nucleosomes that have an affinity for GBM components. In situ immune complex formation also occurs when anti-dsDNA antibodies cross-react with glomerular structural proteins such as alpha-actinin, laminin, and annexin II. Defective clearance of apoptotic debris contributes to the ongoing exposure of nuclear autoantigens, perpetuating the autoimmune response.

Complement Activation

Classical complement pathway activation is a hallmark of lupus nephritis. C1q binds to IgG and IgM within the deposited immune complexes, initiating a cascade that consumes C4 and C3. Low serum C3 and C4 levels are therefore hallmarks of active lupus nephritis, and their levels correlate inversely with disease activity. Paradoxically, inherited deficiency of early complement components, including C1q, C2, and C4, predisposes to the development of SLE itself, as these complement proteins normally facilitate the clearance of immune complexes and apoptotic debris. Terminal complement activation through the membrane attack complex C5b-9 contributes directly to podocyte and endothelial injury within the glomerulus.

Type I Interferon

Plasmacytoid dendritic cells produce interferon-alpha in response to nucleic acid-containing immune complexes, and the resulting interferon signature is a key driver of disease activity in SLE. This pathway has become an important therapeutic target, as demonstrated by the efficacy of anifrolumab, a type I interferon receptor antagonist, in the management of systemic lupus erythematosus.

ISN/RPS Classification (2003, revised 2018)

Class I: Minimal Mesangial LN

Class I lupus nephritis is characterized by a normal appearance on light microscopy, with immune deposits limited to the mesangium and detectable only on immunofluorescence or electron microscopy. This class is usually subclinical and does not require specific treatment beyond management of the underlying systemic disease.

Class II: Mesangial Proliferative LN

Class II lupus nephritis demonstrates mesangial hypercellularity on light microscopy accompanied by mesangial immune deposits. Clinically, patients present with mild proteinuria and microscopic hematuria. Treatment is generally limited to supportive care with or without low-dose corticosteroids, and RAAS blockade is indicated for proteinuria management.

Class III: Focal LN (<50% of glomeruli)

Class III lupus nephritis is a focal proliferative lesion affecting fewer than 50 percent of glomeruli, and it is further subclassified as active, chronic, or active and chronic based on the nature of the histologic changes. The characteristic histologic findings include subendothelial immune deposits with endocapillary proliferation. Patients typically present with a nephritic picture featuring active urine sediment, and treatment requires induction immunosuppression.

Class IV: Diffuse LN (≥50% of glomeruli)

Class IV lupus nephritis is the most common and most severe class, accounting for approximately 40 percent of lupus nephritis biopsies. It is further subclassified as segmental (IV-S) or global (IV-G) based on the distribution of lesions within affected glomeruli. The histologic hallmarks include extensive subendothelial deposits that produce the characteristic wire-loop lesions on light microscopy, endocapillary proliferation, and frequently crescents. The clinical presentation combines nephritic and nephrotic features, with active urine sediment, acute kidney injury, and hypertension. Aggressive induction immunosuppression is the cornerstone of treatment.

Class V: Membranous LN

Class V lupus nephritis is characterized by subepithelial immune deposits in a pattern similar to primary membranous nephropathy, and patients typically present with nephrotic syndrome. Class V may occur in isolation or in combination with class III or IV disease. The full-house immunofluorescence pattern, with staining for IgG, IgA, IgM, C3, and C1q, distinguishes lupus-associated membranous nephropathy from primary membranous nephropathy. Pure class V may respond to immunosuppression or supportive care, but when combined with class III or IV disease, treatment should be directed at the proliferative component.

Class VI: Advanced Sclerosing LN

Class VI lupus nephritis represents the end stage of renal involvement, defined by more than 90 percent globally sclerosed glomeruli. This class reflects irreversible, burned-out disease, and there is no benefit from immunosuppressive therapy. Management should focus on preparation for renal replacement therapy.

<image>Visual comparison of the ISN/RPS lupus nephritis classification showing six glomerular cross-sections. Class I: normal-appearing glomerulus with subtle mesangial deposits visible only on IF/EM. Class II: mesangial hypercellularity with mesangial deposits. Class III: focal proliferative lesion affecting <50% of glomeruli, showing endocapillary proliferation and subendothelial deposits in a segmental distribution. Class IV: diffuse proliferative lesion affecting ≥50% of glomeruli with extensive subendothelial deposits (wire-loop pattern), endocapillary proliferation, and possible crescents. Class V: thickened GBM with subepithelial deposits and spike formation, similar to membranous nephropathy pattern. Class VI: globally sclerosed glomerulus with fibrosis. For each class, include a small IF inset showing the "full-house" pattern (IgG, IgA, IgM, C3, C1q) where applicable. Label typical clinical presentation and prognosis beneath each class.</image>

Diagnosis

Clinical Features

The clinical features of lupus nephritis include an active urine sediment with hematuria and red blood cell casts, proteinuria exceeding 0.5 grams per day or a urine protein-to-creatinine ratio greater than 0.5 g/g, rising serum creatinine, and hypertension. Serologic markers are central to the diagnosis: anti-dsDNA antibodies are typically elevated and correlate with disease activity, C3 and C4 levels are characteristically low reflecting classical complement pathway consumption, and ANA is positive.

Indications for Renal Biopsy

Renal biopsy is indicated in SLE patients with proteinuria exceeding 0.5 grams per day or a UPCR greater than 0.5, active urine sediment with dysmorphic red blood cells or cellular casts, or an unexplained rise in serum creatinine. The biopsy is essential because it guides the ISN/RPS classification, provides activity and chronicity scoring, and directly informs treatment decisions. Repeat biopsy is indicated for treatment failure, relapse with unclear class, or a change in clinical presentation that may signify class transformation.

Activity and Chronicity Indices (NIH Scoring)

The NIH activity index, scored from 0 to 24, assesses potentially reversible lesions including endocapillary proliferation, leukocyte infiltration, wire-loop deposits, fibrinoid necrosis and karyorrhexis (weighted by a factor of 2), cellular crescents (also weighted by 2), and interstitial inflammation. A high activity score supports the use of aggressive immunosuppressive therapy. The chronicity index, scored from 0 to 12, evaluates irreversible damage including glomerular sclerosis, fibrous crescents, tubular atrophy, and interstitial fibrosis. A high chronicity score predicts a diminished likelihood of response to immunosuppression and portends progression to end-stage renal disease.

Biomarkers of Activity

Anti-dsDNA antibody levels rise during disease flares, particularly in class III and IV lupus nephritis, and serve as a useful marker of disease activity. Serum C3 and C4 levels fall with active disease as a result of classical complement pathway consumption. Urinary biomarkers including NGAL, MCP-1, and TWEAK correlate with histologic activity and represent promising tools for non-invasive disease monitoring, though they remain in the research stage and are not yet incorporated into routine clinical practice.

Treatment

Induction Therapy (Class III/IV ± V)

Mycophenolate Mofetil (MMF) + Glucocorticoids

Mycophenolate mofetil at a target dose of 2 to 3 grams per day for 6 months, combined with glucocorticoids, is a preferred induction regimen for lupus nephritis. The ALMS trial, published in 2009, demonstrated that MMF was non-inferior to intravenous cyclophosphamide for induction therapy. MMF-based induction is particularly preferred in African American and Hispanic patients, in whom it has demonstrated superiority over cyclophosphamide. Concurrent glucocorticoid therapy typically begins with intravenous methylprednisolone 250 to 500 mg for 3 days, followed by oral prednisone at 0.5 to 1 mg/kg/day, which is then tapered to less than 7.5 mg per day by 3 to 6 months.

Cyclophosphamide + Glucocorticoids

The Euro-Lupus protocol employs low-dose intravenous cyclophosphamide at 500 mg every 2 weeks for 6 doses, followed by azathioprine maintenance therapy. This regimen was shown in the Euro-Lupus Nephritis Trial to achieve equivalent efficacy with significantly less toxicity compared to the traditional NIH high-dose protocol, which uses 0.5 to 1 g/m2 intravenously monthly for 6 months. The high-dose NIH protocol is now reserved for severe proliferative lupus nephritis with crescents or rapidly declining glomerular filtration rate.

Voclosporin + MMF (AURORA Trial)

Voclosporin is a novel calcineurin inhibitor with more predictable pharmacokinetics than cyclosporine, eliminating the need for routine trough monitoring. The AURORA trial, published in 2021, demonstrated that voclosporin at 23.7 mg twice daily combined with MMF and low-dose steroids significantly increased the complete renal response rate compared to MMF and steroids alone, achieving 41 percent versus 23 percent at 52 weeks. Voclosporin received FDA approval in 2021 for active lupus nephritis, making it the first oral drug specifically approved for this indication. It is added to the MMF backbone and allows for more rapid corticosteroid tapering.

Belimumab + Standard of Care (BLISS-LN)

Belimumab is a monoclonal antibody directed against B-lymphocyte stimulator (BAFF/BLyS), a cytokine essential for B-cell survival and differentiation. The BLISS-LN trial, published in 2020, demonstrated that adding belimumab to standard of care, whether MMF-based or cyclophosphamide followed by azathioprine, improved the primary efficacy renal response compared to standard of care alone, achieving 43 percent versus 32 percent at week 104. Belimumab received FDA approval for active lupus nephritis in 2020 and can be added to either MMF-based or cyclophosphamide-based induction regimens.

Maintenance Therapy

Mycophenolate mofetil at 1 to 2 grams per day is the preferred maintenance agent, supported by the ALMS maintenance and MAINTAIN-Nephritis trials. Azathioprine at 2 mg/kg/day serves as an alternative and is the standard maintenance agent following cyclophosphamide induction in the Euro-Lupus protocol. Maintenance therapy should be continued for a minimum of 3 to 5 years, and many patients require indefinite maintenance immunosuppression. The corticosteroid taper should aim for a prednisone dose of 5 mg per day or less, with the goal of complete discontinuation by 12 to 24 months when feasible. Hydroxychloroquine at 200 to 400 mg per day should be prescribed for all SLE patients regardless of renal involvement, as it reduces renal flares by approximately 50 percent, reduces overall mortality, and provides anti-thrombotic benefits. Patients on hydroxychloroquine require monitoring for retinal toxicity.

Class V (Pure Membranous) LN

The management of pure class V lupus nephritis depends on the degree of proteinuria. Patients with subnephrotic proteinuria can be managed with supportive care including RAAS blockade and hydroxychloroquine. Those with nephrotic-range proteinuria require immunosuppressive therapy, with MMF plus corticosteroids being the preferred approach and cyclosporine serving as an alternative. When class V occurs in combination with class III or IV disease, treatment should be directed at the proliferative component.

<image>Treatment timeline for lupus nephritis class IV showing induction and maintenance phases. Induction phase (months 0-6): show three parallel options: (1) MMF 2-3 g/day + pulse methylprednisolone then oral prednisone taper, (2) Euro-Lupus IV cyclophosphamide 500 mg q2wk x 6 doses + prednisone, (3) Voclosporin 23.7 mg BID + MMF + low-dose steroids. All options can include belimumab add-on. Show hydroxychloroquine 200-400 mg/day as universal background therapy. Transition to maintenance phase (months 6 onwards): MMF 1-2 g/day or azathioprine 2 mg/kg/day with continued prednisone taper to ≤5 mg/day. Show monitoring schedule: serum creatinine, UPCR, C3/C4, anti-dsDNA every 1-3 months. Include criteria for complete renal response (UPCR <0.5, stable or improved GFR, inactive sediment) and partial renal response (≥50% reduction in proteinuria).</image>

Special Considerations

Lupus Podocytopathy

Lupus podocytopathy is a distinct entity in which SLE patients present with a minimal change disease or FSGS-like presentation without immune complex-mediated glomerular injury. The full-house immunofluorescence pattern may be minimal or confined to the mesangium, and electron microscopy reveals diffuse foot process effacement without the subepithelial or subendothelial deposits characteristic of proliferative or membranous lupus nephritis. This entity responds to corticosteroids in a manner similar to primary minimal change disease or FSGS. Recognizing lupus podocytopathy is clinically important because its treatment differs fundamentally from that of class III or IV lupus nephritis.

Thrombotic Microangiopathy in LN

Thrombotic microangiopathy can occur in the setting of lupus nephritis, most commonly driven by antiphospholipid antibody syndrome, which produces a thrombotic vasculopathy that may coexist with immune complex-mediated glomerulonephritis. Distinguishing thrombotic microangiopathy from active proliferative lupus nephritis on renal biopsy is critical because the treatments are fundamentally different: thrombotic microangiopathy requires anticoagulation, whereas proliferative lupus nephritis requires immunosuppression.

Pregnancy in LN

Pregnancies in women with lupus nephritis should be carefully planned during periods of disease remission, ideally when the disease has been quiescent for at least 6 months. Active lupus nephritis during pregnancy significantly increases the risk of pre-eclampsia, fetal loss, and preterm delivery. Medications considered safe during pregnancy include hydroxychloroquine, which should be continued throughout pregnancy, azathioprine, low-dose corticosteroids, and tacrolimus. Mycophenolate mofetil is teratogenic and must be discontinued at least 3 months before conception, and cyclophosphamide and voclosporin are similarly contraindicated. Distinguishing a lupus nephritis flare from pre-eclampsia can be challenging, as both cause proteinuria and hypertension; low complement levels and rising anti-dsDNA titers favor a lupus nephritis flare.

Transplant in ESRD from LN

SLE disease activity generally decreases in patients who reach end-stage renal disease or begin dialysis. Lupus nephritis recurrence in the allograft is relatively uncommon, occurring in only 2 to 10 percent of cases at a clinically significant level. Transplant outcomes in SLE patients are excellent, and there is no contraindication to transplantation. Hydroxychloroquine should be continued post-transplant.

Key Clinical Pearls

• The "full-house" IF pattern (IgG, IgA, IgM, C3, C1q) is nearly pathognomonic for lupus nephritis; if found incidentally on biopsy, evaluate for SLE even if clinical diagnosis is not established
• Hydroxychloroquine is the single most important medication for ALL SLE patients: it reduces renal flares, mortality, thrombosis, and damage accrual; never discontinue HCQ
• Voclosporin (AURORA trial) and belimumab (BLISS-LN) represent the first targeted therapies approved for LN and should be considered as add-on to MMF-based induction
• The chronicity index on renal biopsy predicts response to treatment: high chronicity (glomerular sclerosis, tubular atrophy, interstitial fibrosis) means less reversible disease and tempered immunosuppression expectations
• Distinguish lupus podocytopathy from class III/IV LN: the former presents as nephrotic syndrome with diffuse foot process effacement but minimal immune complex deposition, and responds to steroids like MCD

References

1. Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the International Society of Nephrology/Renal Pathology Society Classification for Lupus Nephritis. Kidney Int. 2018;93(4):789-796.
2. Rovin BH, Teng YKO, Gingzler EM, et al. Efficacy and Safety of Voclosporin versus Placebo for Lupus Nephritis (AURORA 1). Lancet. 2021;397(10289):2070-2080.
3. Furie R, Rovin BH, Houssiau F, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis (BLISS-LN). N Engl J Med. 2020;383(12):1117-1128.
4. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis (ALMS). J Am Soc Nephrol. 2009;20(5):1103-1112.
5. Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-Year Follow-Up Data of the Euro-Lupus Nephritis Trial (ELNT). Ann Rheum Dis. 2010;69(1):61-64.

Read this lecture as Markdown